Management 's focus on generating revenues sets this stock apart from others. Consider the following in the context of the recently publicised dangers associated with periodic use of codeine-based painkillers and the need for natural alternatives:
"Further to this significant development, the Company also advises that it is in ongoing discussions with the Department of Health to import Linnea’s proprietary CBD oil products. Pending this approval, Bod will begin to generate revenues as it is made available to patients through Special Access Scheme Category B. Board and management look forward to updating the market as these discussions progress. "
